Moffitt Cancer Center | Strategic Alliance Partners

January 12, 2024

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

January 12, 2024

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

January 11, 2024

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.

January 11, 2024

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

January 10, 2024

Michael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.

January 10, 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

January 10, 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

January 09, 2024

Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.

January 09, 2024

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

January 04, 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

January 03, 2024

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

January 02, 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

January 02, 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

January 02, 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

December 19, 2023

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

December 18, 2023

Experts on follicular lymphoma discuss first-line treatment options available for patients.

December 15, 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

November 15, 2023

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.

November 07, 2023

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.

November 02, 2023

Andrew T. Kuykendall, MD, discusses the importance of the approval of momelotinib in the treatment of patients with anemic symptomatic myelofibrosis, key efficacy and safety data from the MOMENTUM trial that supported the decision, and unanswered questions regarding the agent’s potential role in other subsets within this population.